My primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell-tumour antigens; and the detection and treatment of minimal residual disease in leukaemia and lymphoma.
Expression of FOXP3, CD68 and CD20 at Diagnosis in the Microenvironment of Classical Hodgkin Lymphoma is Predictive of outcome. J Clin Oncol (2013) 31(2):256-62. PMID: 23045593
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA (2009) 106(15):6250-5. PMID: 19332800
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest (2008) 118(7):2427-37. PMID: 18551193
SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. Blood (2008) 112(2):394-7. PMID: 18434611
The research interest of my group focuses on immunological approaches to the treatment of haematological cancers. In particular, we are interested in understanding:
Evaluating an interactive acceptance and commitment therapy (ACT) workshop delivered to trained therapists working with cancer patients in the United Kingdom: a mixed methods approach Moschopoulou E, Brewin D, Ridge D et al. BMC Cancer (2022) 22(7)
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee Campo E, Jaffe ES, Cook JR et al. Blood (2022) 140(7) 1229-1253
NK cells CD56bright and CD56dim subset cytokine loss and exhaustion is associated with impaired survival in myeloma. Seymour F, Cavenagh JD, Mathews J et al. Blood Adv (2022) 6(2) 5152-5159
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial Moreno C, Greil R, Demirkan F et al. Haematologica (2022) 107(7) 2108-2120
How a Medical Association Can Make a Difference in a Crisis Situation. van Havre N, Orsini E, Almeida A et al. Hemasphere (2022) 6(2) e765
Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma Ghione P, Palomba ML, Patel AR et al. Blood (2022) 140(7) 851-860
Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms. de Leval L, Alizadeh AA, Bergsagel PL et al. Blood (2022) (2)
Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type Diffuse Large B Cell Lymphoma. Bewicke-Copley F, Korfi K, Araf S et al. Blood Adv (2022) (2)
PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T cell exhaustion. Taylor JG, Truelove E, Clear A et al. Haematologica (2022) (2)
Genomic and microenvironmental landscape of stage I follicular lymphoma, compared to stage III/IV. Los-de Vries GT, Stevens WBC, van Dijk EV et al. Blood Adv (2022) (2)
Clinical Research Fellows
Dr Jennifer Edelmann, Dr Robin Sanderson, Dr Joseph Taylor, Dr Edward Truelove
I hold the Gordon Hamilton Fairley Chair of Medical Oncology at St. Bartholomew's Hospital, Barts Cancer Institute, Queen Mary, University of London. My doctoral studies were performed at University College London as the recipient of a Wellcome Trust Fellowship Award. I continued post-doctoral training with Professor Lee Nadler at the Dana-Farber Cancer Institute, Harvard Medical School.
In 1992, I was appointed to the Faculty at Harvard Medical School, where I remained as Associate Professor of Medicine and an Attending Physician at the Dana-Farber Cancer Institute and Brigham and Women's Hospital, until returning to London in 2005. I am a founding member of the CLL Research Consortium, Associate Editor of Blood and was elected a Fellow of the Academy of Medical Science.